Company: CERO
Filing Date: 2025-09-05
Form Type: 8-K
Source: 0001213900-25-084737
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-09-05
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events.

On
September 5, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “ Company”), issued a press release announcing
that the Company received Fast Track Designation from the U. S. Food and Drug Administration in relation to the Company’s lead investigational
compound, CER-1236 for Acute Myeloid Leukemia (AML). A copy of the press release is attached herewith as Exhibit 99.1 to this Current
Report on Form 8-K.

Item 9.01
Financial Statements and Exhibits.

(d)
Exhibits

  Exhibit      Description                                                             
      No.                                                                              
     99.1      Press release, dated September 5, 2025.                                 
 ───────────────────────────────────────────────────────────────────────────────────────
      104      Cover                                                                   

SIGNATURE

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

  Dated: September 5, 2025      CERO THERAPEUTICS HOLDINGS, INC.                               
 ───────────────────────────────────────────────────────────────────────────────────────────────
                                By:                                   /s/                      
                                Name:                                 Chris Ehrlich            
                                Title:                                Chief Executive Officer